BioSpace News Archive

Erasca, Inc., a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, announced its participation in the Morgan Stanley Global Healthcare Conference.

Zoetis Inc. (NYSE:ZTS) will participate in the Morgan Stanley 20th Annual Global Healthcare Conference on Tuesday, September 13, 2022.

Vistagen Therapeutics, Inc. announced that Chief Executive Officer, Shawn Singh, will participate in the following upcoming investor conferences in New York.

GlycoMimetics, Inc. announced that the compensation committee of the Company’s Board of Directors approved the grant on September 2, 2022 of a non-qualified stock option award to purchase an aggregate of 200,000 shares of common stock to Edwin P. Rock, M.D., the Company’s new Senior Vice President and Chief Medical Officer.

Danny Yeung, CEO & Co-founder of Prenetics, said, “The current and next fiscal year are critical periods of transformative growth for Prenetics.

Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, announced that it will participate in the Guggenheim Nantucket Therapeutics Conference, September 27th to 29th.

Stevanato Group S.p.A. announced that management will present at the Bank of America Global Healthcare Conference in London at 9:05 a.m. on September 15, 2022.

IMAC Holdings, Inc. (Nasdaq: BACK) (“IMAC” or “the Company”), today announces it has completed the third cohort of its Phase 1 clinical trial for its investigational compound utilizing umbilical cord-derived allogenic mesenchymal stem cells for the treatment of bradykinesia due to Parkinson’s disease.

Immunocore Holdings plc (Nasdaq: IMCR), has released today initial Phase 1 data for the first off-the-shelf ImmTAC® targeting PRAME, demonstrating that IMC-F106C is well tolerated and resulted in durable responses across multiple solid tumor types.

Progyny, Inc. (Nasdaq: PGNY), a leading benefits management company specializing in fertility and family building benefits solutions, today announced that Pete Anevski, Progyny’s Chief Executive Officer, and Mark Livingston, Chief Financial Officer, will participate in a fireside chat at the BofA Securities 2022 Global Healthcare Conference.